Viloxazine trial for preschool kids with ADHD
Part of Mental health clinical trials.
This study tests whether viloxazine extended-release can reduce ADHD symptoms in children ages 4–5. It also checks safety in preschool-age kids, including heart and nervous-system side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 4 years 0 months to 5 years 9 months old at screening and is generally healthy.
- A parent/guardian can sign consent to join the study.
- Your child has a main diagnosis of ADHD, confirmed by structured clinical interviews.
- Your child’s ADHD symptom severity is high on rating scales at screening and start of the study (Visit 2).
- Your child participates in a structured group setting outside the home at least 2 days per week.
- Your child is not starting new behavior therapy in the last 30 days and does not plan major changes during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new extended-release medication called viloxazine for Korean children and teens with ADHD. The goal is to see if it can help improve attention and reduce hyperactivity compared to a placebo (a pill with no medicine).
This trial tests a new extended-release medication called Onyda XR (clonidine) in children aged 6 to 12 who have both ADHD and Oppositional Defiant Disorder. The goal is to see if it helps with symptoms like inattention, hyperactivity, and defiant behavior, and if it is safe.
This study compares stimulant and non-stimulant ADHD medicines in kids who have not taken ADHD medication before. It also studies how these treatments affect brain “reward” processes, which may be linked to substance-use risk.
This trial tests an early intervention program for young children (about ages 3 to 5) with clinically significant attention and behavior symptoms. It may help by targeting ADHD-related difficulties seen at home and school.
This trial tests if the medication Foquest can help treat ADHD symptoms in adults aged 65 and older. It aims to see if it's safe and effective for this age group.
This trial tests starting a new medication (Methylphenidate or Guanfacine) in young children with moderate or severe ADHD to see how well it works and if it’s safe.
Hear when a new ADHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.